Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer

Anouk K.M. Claessens, Jan J.V. Busschbach, on behalf of the Dutch Breast Cancer Research Group (BOOG), Bram L.T. Ramaekers, Frans L.G. Erdkamp, Jeanette M. Bouma, A. Elise van Leeuwen-Stok, Vivianne C.G. Tjan-Heijnen, Monique E.M.M. Bos*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)619-624
Number of pages6
JournalActa Oncologica
Issue number5
Publication statusPublished - 9 Feb 2022

Cite this